The accompanying notes are an integral part of these consolidated financial statements.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL
STATEMENTS
NOTE 1 – BASIS
OF PRESENTATION, GOING CONCERN AND CORRECTION OF PRIOR YEAR INFORMATION
Interim Financial Reporting
While the information presented in the
accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary
to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance
with generally accepted accounting principles in the United States of America ("GAAP"). All adjustments are of a normal,
recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end
audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related
to the three month period ended March 31, 2017. Notes to the financial statements which would substantially duplicate the disclosure
contained in the audited financial statements for fiscal 2016 as reported in the Form 10-K have been omitted. It is suggested that
these interim financial statements be read in conjunction with our audited financial statements and related notes for the year
ended December 31, 2016 included in our Form 10-K filed with the Securities Exchange Commission on May 22, 2017. Operating results
for the three months ended March 31, 2017 are not necessarily indicative of the results that can be expected for the period from
January 1, 2017 through December 31, 2017.
Earnings Per Share
We present both basic and diluted earnings
per share (“EPS”) amounts in our financial reporting. Basic EPS excludes dilution and is computed by dividing
income available to Common Stock holders by the weighted-average number of Common Stock outstanding for the period. Diluted
EPS reflects the maximum potential dilution that could occur from our convertible debt. Potential dilutive shares are excluded
from the calculation if they have an anti-dilutive effect in the period. During the three months ended March 31, 2017, the dilutive
effect of the shares underlying the outstanding convertible debt of the Company was 2,187,000,013 and a reduction to net income
of $621,098.
Going Concern
The accompanying unaudited consolidated
financial statements have been prepared in conformity with GAAP, which contemplates continuation of the Company as a going concern,
which is dependent upon the Company's ability to establish itself as a profitable business. At March 31, 2017, the Company has
an accumulated deficit of $6,823,653 and has a working capital deficit of $1,091,309. These matters raise substantial doubt about
the Company's ability to continue as a going concern. These unaudited consolidated financial statements do not include any adjustments
that might result from the outcome of these uncertainties, nor do they include adjustments relating to the recoverability and
realization of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.
The Company’s ability to continue in business is dependent upon obtaining sufficient financing or attaining profitable operations.
However, there can be no assurance that management will be successful in obtaining additional funding or in attaining profitable
operations.
NOTE 2 – STOCKHOLDERS’
DEFICIT
The Company is authorized to issue up to
7,000,000,000 shares of common stock at $0.001 par value per share and 20,000,000 shares of preferred stock at $0.001 par value
per share. As of March 31, 2017 and December 31, 2016, the Company had 801,110,887 and 138,889,083 shares of common stock and 1,000
shares of Series A preferred stock issued and outstanding.
NOTE 3 – RELATED PARTIES
As of March 31, 2017 and December 31, 2016,
the Company has outstanding advances to former officers and directors aggregating $22,675. The advances are unsecured, due on demand
and bear no interest and are reported as accounts payable.
NOTE 4 – CONVERTIBLE NOTES PAYABLE
At March 31, 2017 and December 31, 2016, convertible notes payable
consisted of the following:
|
|
March 31, 2017
|
|
|
December 31, 2016
|
|
Convertible notes payable
|
|
$
|
691,102
|
|
|
$
|
1,054,865
|
|
Unamortized debt discounts
|
|
|
(170,059
|
)
|
|
|
(80,469
|
)
|
Total
|
|
$
|
521,043
|
|
|
$
|
974,396
|
|
The outstanding convertible notes bear
interest from 8% to 12%, are due on demand and are convertible into common stock at variable rates based upon discounts ranging
from 25% to 70% to the lowest trading price of the common stock for 10 to 20days prior to conversion. The Company identified embedded
derivatives related to the outstanding convertible notes. These embedded derivatives included certain conversion features. The
accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as
of the inception date of the convertible notes and to adjust the fair value as of each subsequent balance sheet date. At
March 31, 2017, the aggregate fair value of the outstanding derivative liabilities was determined to be $413,298. The fair value
of the embedded derivatives was determined using the lattice model created by a third party valuation based on the following assumptions:
The fair value of the outstanding embedded
derivatives of $413,298 at March 31, 2017 was determined using the Lattice Pricing Model with the following assumptions:
Dividend yield:
|
|
|
-0-%
|
|
Market price of common stock:
|
|
|
$0.0014
|
|
Expected volatility:
|
|
|
Maximum
|
|
Risk free rate:
|
|
|
1.11%
|
|
At March 31, 2017, the Company adjusted
the recorded fair value of the derivative liability to market resulting in non-cash, non-operating loss of $570,379 for the three
months ended March 31, 2017.
Notes in default and included in Current
Notes Payable were $691,102 at March 31, 2017.
NOTE 5 - FAIR VALUE OF FINANCIAL
INSTRUMENTS
ASC 825-10 defines fair value as the price
that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions
that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk
of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs
and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be
used to measure fair value:
Level 1 - Quoted prices in active markets
for identical assets or liabilities.
Level 2 - Observable inputs other than
Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived
principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs to the valuation
methodology that are significant to the measurement of fair value of assets or liabilities.
To the extent that valuation is based on
models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment.
In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases,
for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed is determined
based on the lowest level input that is significant to the fair value measurement.
Items recorded or measured at fair value
on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of March 31,
2017 and December 31, 2016:
|
|
Total
|
|
|
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
|
|
|
Significant
Other
Observable
Inputs (Level 2)
|
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
March 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liabilities
|
|
$
|
413,298
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
413,298
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liabilities
|
|
$
|
1,143,830
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
1,143,830
|
|
The derivative liabilities are measured
at fair value using the Latrtice Pricing Model including quoted market prices and estimated volatility factors based on historical
prices for the Company’s common stock and are classified within Level 3 of the valuation hierarchy.
The following table provides a summary
of changes in fair value of the Company’s Level 3 financial liabilities for the three months ended March 31, 2017:
|
|
Derivative Liabilities
|
|
|
Balance, December 31, 2016, adjusted
|
|
$
|
857,784
|
|
Additions at fair value
|
|
|
125,893
|
|
Change in fair value
|
|
|
(570,379
|
)
|
Balance, March 31, 2017
|
|
$
|
413,298
|
|
The Company changed its derivative pricing
model from Black-Scholes to a better defined Lattice pricing model for the year ended December 31, 2017. This change caused a restatement
of the income for the period ended March 31, 2016 represented in this filing. The changes were to the Derivative Liability Expense
increasing $157,602 with the same increase to the balance sheet account Derivative Liability.
NOTE 6 – NOTES PAYABLE
In
January 2017, the Company entered into a convertible debt agreement with a principal amount of $53,000 with 8% interest per annum.
This note is convertible at a 42% discount to the average of the three lowest intraday trading price of the 10 days preceding
the conversion request. This note becomes convertible at or after maturity (180 days). The default interest rate is 22% per annum.
In
February 2017, the Company entered into a convertible debt agreement with a principal amount of $33,000 with 12% interest per
annum. This note is convertible at a 42% discount to the average of the three lowest intraday trading price of the 10 days preceding
the conversion request. This note becomes convertible at or after maturity (180 days). The default interest rate is 22% per annum.
In
February 2017, the Company entered into a convertible debt agreement with a principal amount of $200,000 with 12% interest per
annum. The Company had received $40,000 as of the filing date. This note is convertible at a 42% discount to the average of the
lowest intraday trading price of the 25 days preceding the conversion request. This note is payable one year from each tranche
date. The lender may convert at anytime at its choice. The default interest rate is 22% per annum.
NOTE 7– SUBSEQUENT EVENTS
In April 2017, the
Company issued 390,027,368 common shares in satisfaction of $106,485 of convertible debt.
An update on a prior Form 8-K
On September 23,
2016 FBEC Worldwide, Inc. ("FBEC") announced that it had received a purchase order for 35,000 units from Four Link USA.
Once the purchase order was received FBEC immediately contacted their existing co-packer. There were plans and the start of production
for the 35,000 units of product. However, increasing delays and improper formulation and branding quickly became an issue with
regard to the then co-packer. FBEC made a decision to terminate the agreement with their then co-packer and begin seeking out a
new solution. This process put the purchase order we received on hold.
FBEC thought it
was in the best interest of the company to make sure there was a finished and polished product before fulfilling any purchase orders.
On 5/23/2017 FBEC confirmed that Four Link USA is still interested in the product and has requested that FBEC send them a sample
of the product with the new branding material and is considering a new purchase order in the near future for their new Healthy
Hemp Energy Shot Product.